Cell and gene remedy are promising fields of biomedical analysis that target growing new remedies for a spread of ailments by modifying cells and genes.
On one hand, a cell remedy includes the usage of residing cells as therapeutic brokers to deal with quite a lot of medical circumstances, together with most cancers, immune problems, and genetic ailments. The cells utilized in these therapies could be both from the affected person’s personal physique (autologous) or from a donor (allogeneic).
And, then again, a gene remedy includes the usage of genetic materials, equivalent to DNA or RNA, to deal with or forestall illness by modifying the expression of genes. This may be finished by changing a lacking or faulty gene, introducing a brand new gene to assist the physique battle illness, or modifying an present gene to right a mutation.
Presently, these two therapies are witnessing a technological transformation within the type of biomanufacturing 4.0.
Biomanufacturing 4.0 is a brand new strategy to biomanufacturing that integrates superior applied sciences, equivalent to automation, synthetic intelligence, machine studying, and large knowledge analytics, to enhance the effectivity, high quality, and scalability of bioproduction processes. It is usually referred to as “digital biomanufacturing” or “good biomanufacturing.”
Within the context of biotechnology and life sciences, biomanufacturing refers back to the manufacturing of biologics, equivalent to vaccines, antibodies, proteins, and different biopharmaceuticals, utilizing residing cells or organisms.
Biomanufacturing 4.0 goals to optimize this course of by leveraging digital applied sciences to raised management and monitor the manufacturing course of, cut back human error, and allow real-time knowledge evaluation and decision-making.
So, how precisely is that this new revolution in cell and gene remedy going to impression the general healthcare sector? To know this, and extra, BIS Analysis is conducting a webinar by involving among the brightest minds from the sector of biopharma and healthcare manufacturing.
Listed here are all the main points:
Webinar Matter: Biomanufacturing 4.0 | A New Period in Cell and Gene Remedy Improvement
Agenda:
The primary agenda of this webinar is to grasp and discover the next:
• Cell and Gene Remedy Biomanufacturing Market: Developments and Key Developments
• Awaited Applied sciences within the Cell and Gene Remedy Improvement
• Regulatory State of affairs – GMP/cGMP Pointers
• Biomanufacturing 4.0 – Adoption State of affairs
• Conclusion and Future Outlook
Audio system:
Our eminent panellists for this webinar can be:
Dr. Likhesh Sharma – Dr. Likhesh Sharma comes with over 15 years of intensive expertise within the subject of biotechnology. His experience ranges from protein engineering and characterization to cell evaluation and cell remedy.
He earned his Ph.D. in Biophysics from the Indian Institute of Science, Bangalore, and an undergraduate honors diploma from Delhi College. In his present position, he works intently with the business and academia for the event of cell remedy in India whereas overseeing the South Asia area for Cytiva Cell Remedy as a product supervisor.
Mario Novoa Belman – Mr. Mario Novoa Belman is an purposes specialist and technical consultant at Infors LATAM. He has greater than 20 years of expertise within the subject of biotechnology. He’s a biotechnologist engineer with a specialty in organic manufacturing and graduated from the Interdisciplinary Skilled Unit of Biotechnology (UPIBI) of the Nationwide Polytechnic Institute (IPN).
He has in depth expertise within the care of mammalian cell cultures, preservation and upkeep of genetically modified clones, technology of Normal Working Procedures, formulation and sterilization of tradition media, meeting, preparation and sterilization of bioreactors, and calibration and adjustment of kit concerned.
He was a part of the workforce of consultants and product specialists at Sartorius de México.
Akash Mhaskar – Akash Mhaskar is a principal analyst, healthcare, and leads the cell and gene remedy phase at BIS Analysis. He has about eight years of expertise in healthcare market analysis and consulting. He comes with a wealthy expertise in pharma and med-tech area, with specialization in aggressive evaluation, epidemiology modeling, and impression evaluation.
Stuti Kandpal – Stuti Kandpal is working as a senior analysis affiliate with BIS Analysis within the cell and gene remedy/pharma workforce. She has finished her grasp’s in biotechnology from Gautam Buddha College and has beforehand labored at International Knowledge Analysis Middle (GDRC) in Hyderabad. She has an expertise of about two years in market analysis.
Why do you have to attend the webinar?
Aside from the truth that a number of of knowledgeable minds from the pharma business can be part of this in depth webinar, this can be an awesome alternative for you study:
• To Perceive the Ecosystem of Cell and Gene Remedy Improvement
• To Determine Components Limiting the Adoption of Automation in Biomanufacturing
• To Discover Upcoming Applied sciences in Cell and Gene Remedy Biomanufacturing
• To Discover Market Alternatives in Completely different Areas
• To Analyse the Futurist State of affairs of the Cell and Gene Remedy Biomanufacturing Trade
Timing and Registration:
The webinar goes to happen on twenty eighth Feb’23 at following world timings:
• 7:30 A.M. (EST)
• 12:30 P.M. (GMT)
• 6:00 PM (IST)
Register for the occasion as we speak. Get an edge over your rivals by studying the evolution of Biomanufacturing 4.0.
